Advertisement

PharmacoEconomics & Outcomes News

, Volume 838, Issue 1, pp 32–32 | Cite as

Vedolizumab good value in ulcerative colitis in Japan

Clinical study
  • 9 Downloads

Reference

  1. Hernandez L, et al. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan. PharmacoEconomics : 24 Sep 2019. Available from: URL: https://doi.org/10.1007/s40273-019-00841-1

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations